Fluticasone propionate

Generic Name: Fluticasone propionate

Brand Names: Advair, Airduo, Airduo Respiclick, Aller-flo, Armonair, Beser, Cutivate, Dymista, Flonase, Flovent, Fluticare, Ticanase, Wixela, Xhance

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₁F_₃O_₅S

CAS Number: 80474-14-2

Unique Ingredient Identifier: O2GMZ0LF5W

Background: Fluticasone propionate is a synthetic glucocorticoid. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications. Fluticasone propionate was first approved in 1990.

Indication: Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisas well as inflammatory and pruritic dermatoses. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis.

Associated Conditions: Allergic Rhinitis (AR), Allergy to Animal Dander, Allergy to Mold, Allergy to Tree Pollen, Asthma, Bacterial Sinusitis, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Chronic Sinusitis, Dermatitis, Emphysema, Eosinophilic Esophagitis, House Dust Mite Allergy, House dust allergy, Itching of the nose, Nasal Congestion, Non-Allergic Rhinitis, Rhinitis, Rhinitis Perennial, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Moderate, severe Perennial Allergic Rhinitis (PAR), Moderate, severe Seasonal Allergic Rhinitis

Associated Therapies: -

Clinical Trials

Responsiveness of Lower Airways in Adult Patients (18-60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate (BY9010/NL-101)

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Ciclesonide
Drug: Fluticasone

First Posted Date: 2006-03-23

Last Posted Date: 2017-02-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 37

Registration Number: NCT00306163

Locations: 🇳🇱
Altana Pharma/Nycomed, RB Groningen, Netherlands

Study Of Patients With Allergic Rhinitis And Asthma

Phase 4

Completed

Conditions: Asthma

First Posted Date: 2006-02-27

Last Posted Date: 2016-10-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 600

Registration Number: NCT00296530

Locations: 🇺🇸
GSK Investigational Site, Charlottesville, Virginia, United States

A Study in Healthy Volunteers to Evaluate Serum and Urine Levels of the Investigational Product Versus Comparator.

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2006-01-23

Last Posted Date: 2008-03-07

Lead Sponsor: Dey

Target Recruit Count: 30

Registration Number: NCT00280358

Locations: 🇺🇸
Research Site, Lenexa, Kansas, United States

Topical Steroid Treatment for Eosinophilic Esophagitis

Phase 2

Completed

Conditions: Eosinophilic Esophagitis

Interventions: Drug: Fluticasone
Drug: Placebo

First Posted Date: 2006-01-12

Last Posted Date: 2012-05-08

Lead Sponsor: Mayo Clinic

Target Recruit Count: 42

Registration Number: NCT00275561

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders

Phase 3

Completed

Conditions: Eosinophilic Esophagitis

First Posted Date: 2005-12-19

Last Posted Date: 2013-04-11

Lead Sponsor: Marc Rothenberg

Target Recruit Count: 30

Registration Number: NCT00266578

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Non-invasive Measures of Distal Lung Disease in Asthmatics

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: Advair
Drug: QVAR
Drug: Servent Diskus

First Posted Date: 2005-11-08

Last Posted Date: 2021-12-02

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 34

Registration Number: NCT00250341

Locations: 🇺🇸
UCLA, Los Angeles, California, United States

Enhancement of in-Vitro GC Function in Patients With COPD

Phase 2

Completed

Conditions: COPD

Interventions: Drug: placebo
Drug: Fluticasone Propionate
Drug: Theophylline

First Posted Date: 2005-10-19

Last Posted Date: 2019-12-04

Lead Sponsor: Imperial College London

Target Recruit Count: 49

Registration Number: NCT00241631

Locations: 🇬🇧
Windsor chest clinic KEVII Hospital, Windsor, Berks, United Kingdom

The Effect of Salmeterol on Eosinophil (EOS) Function

Not Applicable

Completed

Conditions: Allergic Asthma

Interventions: Drug: Placebo
Drug: salmeterol
Drug: Fluticasone

First Posted Date: 2005-09-21

Last Posted Date: 2017-11-21

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 36

Registration Number: NCT00214019

Locations: 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States

COPD on Primary Care Treatment (COOPT)

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Bronchitis, Chronic

First Posted Date: 2005-09-16

Last Posted Date: 2010-03-12

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 270

Registration Number: NCT00184977

Locations: 🇳🇱
Department of Family Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
🇳🇱
Department of Family Medicine, University of Maastricht, Maastricht, Netherlands

Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE® Inhaler Are Trademarks of GSK Group of Companies.

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: Salmeterol/fluticasone propionate
Drug: Fluticasone propionate

First Posted Date: 2005-09-15

Last Posted Date: 2016-09-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 64

Registration Number: NCT00169546

Locations: 🇬🇧
GSK Investigational Site, Manchester, Lancashire, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy